Leber's Congenital Amaurosis (LCA) stands as a rare, inherited eye condition characterized by profound vision loss either at birth or within the first few months of life. It specifically affects the retina, where the light-sensitive cells (photoreceptors) fail to function properly or degenerate over time. Typical symptoms include involuntary eye movements (nystagmus), sensitivity to light (photophobia), and varying degrees of vision impairment, ranging from severe visual impairment to complete blindness in bright light.
LCA is attributed to mutations in several genes crucial for normal retinal function. These genetic alterations disrupt the production of essential proteins required for vision, affecting the development and maintenance of photoreceptor cells. While a definitive cure for LCA remains elusive, ongoing research, particularly in gene therapy, offers promising avenues for potential treatments. Management currently centers on supportive care, including low-vision aids and strategies to preserve existing vision. Early diagnosis through genetic testing is pivotal for prognosis and may pave the way for future therapeutic advancements.







Title : Lenadogene nolparvovec gene therapy in leber hereditary optic neuropathy
Magali Taiel, GenSight Biologics, France
Title : Stereotactic radiotherapy for wet age-related macular degeneration: year 4 results of a randomised, double-masked, sham-controlled trial
Tim Jackson, King’s College London, United Kingdom